Biomarkers in COPD

Mario Cazzola, Giuseppe Novelli

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Although there is increasing interest in using pulmonary biomarkers for a more complete and clinically relevant assessment of COPD and a plethora of biomarkers are becoming available, there is little information regarding their reproducibility and correlation with other outcome measurements in COPD. The lack of well-validated biomarkers that can be used for monitoring disease activity, predicting future clinical outcomes and the effect of therapeutic interventions highlights the factual need to identify new biomarkers in COPD. It is likely that, using what is called 'integrative functional informatics', which is a novel direction in the interfacing and integration of different technologies (genomics, proteomics, metabolomics and metabonomics, pharmacogenetics, and integrative approaches) for collection and analysis of data on biomarkers, we will be able to identify robust, reliable, and reproducible biomarkers in COPD.

Original languageEnglish
Pages (from-to)493-500
Number of pages8
JournalPulmonary Pharmacology and Therapeutics
Volume23
Issue number6
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Biomarkers
Chronic Obstructive Pulmonary Disease
Metabolomics
Informatics
Pharmacogenetics
Therapeutic Uses
Genomics
Proteomics
Technology
Lung
Monitoring

Keywords

  • Biomarkers
  • COPD
  • Surrogate markers

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)
  • Biochemistry, medical

Cite this

Biomarkers in COPD. / Cazzola, Mario; Novelli, Giuseppe.

In: Pulmonary Pharmacology and Therapeutics, Vol. 23, No. 6, 12.2010, p. 493-500.

Research output: Contribution to journalArticle

Cazzola, Mario ; Novelli, Giuseppe. / Biomarkers in COPD. In: Pulmonary Pharmacology and Therapeutics. 2010 ; Vol. 23, No. 6. pp. 493-500.
@article{2de496cf53884df2bc1591ab258564a4,
title = "Biomarkers in COPD",
abstract = "Although there is increasing interest in using pulmonary biomarkers for a more complete and clinically relevant assessment of COPD and a plethora of biomarkers are becoming available, there is little information regarding their reproducibility and correlation with other outcome measurements in COPD. The lack of well-validated biomarkers that can be used for monitoring disease activity, predicting future clinical outcomes and the effect of therapeutic interventions highlights the factual need to identify new biomarkers in COPD. It is likely that, using what is called 'integrative functional informatics', which is a novel direction in the interfacing and integration of different technologies (genomics, proteomics, metabolomics and metabonomics, pharmacogenetics, and integrative approaches) for collection and analysis of data on biomarkers, we will be able to identify robust, reliable, and reproducible biomarkers in COPD.",
keywords = "Biomarkers, COPD, Surrogate markers",
author = "Mario Cazzola and Giuseppe Novelli",
year = "2010",
month = "12",
doi = "10.1016/j.pupt.2010.05.001",
language = "English",
volume = "23",
pages = "493--500",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press",
number = "6",

}

TY - JOUR

T1 - Biomarkers in COPD

AU - Cazzola, Mario

AU - Novelli, Giuseppe

PY - 2010/12

Y1 - 2010/12

N2 - Although there is increasing interest in using pulmonary biomarkers for a more complete and clinically relevant assessment of COPD and a plethora of biomarkers are becoming available, there is little information regarding their reproducibility and correlation with other outcome measurements in COPD. The lack of well-validated biomarkers that can be used for monitoring disease activity, predicting future clinical outcomes and the effect of therapeutic interventions highlights the factual need to identify new biomarkers in COPD. It is likely that, using what is called 'integrative functional informatics', which is a novel direction in the interfacing and integration of different technologies (genomics, proteomics, metabolomics and metabonomics, pharmacogenetics, and integrative approaches) for collection and analysis of data on biomarkers, we will be able to identify robust, reliable, and reproducible biomarkers in COPD.

AB - Although there is increasing interest in using pulmonary biomarkers for a more complete and clinically relevant assessment of COPD and a plethora of biomarkers are becoming available, there is little information regarding their reproducibility and correlation with other outcome measurements in COPD. The lack of well-validated biomarkers that can be used for monitoring disease activity, predicting future clinical outcomes and the effect of therapeutic interventions highlights the factual need to identify new biomarkers in COPD. It is likely that, using what is called 'integrative functional informatics', which is a novel direction in the interfacing and integration of different technologies (genomics, proteomics, metabolomics and metabonomics, pharmacogenetics, and integrative approaches) for collection and analysis of data on biomarkers, we will be able to identify robust, reliable, and reproducible biomarkers in COPD.

KW - Biomarkers

KW - COPD

KW - Surrogate markers

UR - http://www.scopus.com/inward/record.url?scp=78649333247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649333247&partnerID=8YFLogxK

U2 - 10.1016/j.pupt.2010.05.001

DO - 10.1016/j.pupt.2010.05.001

M3 - Article

C2 - 20471487

AN - SCOPUS:78649333247

VL - 23

SP - 493

EP - 500

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

IS - 6

ER -